Active ingredientCapivasertibCat. No. P-C025-001CAS 1143532-39-1Family · Pharmaceutical analytical standards
Capivasertib
An oral AKT kinase inhibitor, the result of research begun in 2000 at the Institute of Cancer Research in London and approved in the United States in 2023 for certain advanced breast cancers with PIK3CA, AKT1 or PTEN alterations. This family brings together the active ingredient, labelled standards and other impurities.
Did you know?It came out of fragment-based drug design: the starting point was a tiny molecular fragment, 7-azaindole, which chemists "grew" inside the pocket of the AKT enzyme.
Go to the active ingredient →Active ingredientCapivasertibCat. No. P-C025-001CAS 1143532-39-1
Isotopically labelledCapivasertib-d6Cat. No. P-C025-002
ImpurityCapivasertib Impurity 1Cat. No. P-C025-003CAS 886061-26-3
ImpurityCapivasertib Impurity 2Cat. No. P-C025-004No product matches your search.
Need a molecule you cannot find?
Custom synthesis of impurities, metabolites and labelled compounds, with the same characterisation level.